Australia: Clinical governance update - Review of serious failures in reported test results...

Last Updated: 27 September 2016
Article by Alison Choy Flannigan

for Prostate Specific Antigen (PSA) Testing of Patients by SA Pathology; Bankstown-Lidcombe Hospital Medical Gas Findings Report

Clinical governance is the term used to describe a systematic approach to maintaining and improving the quality of patient care within a clinical care setting, health program or health system. It is about the ability to produce effective change so that high quality care is achieved. It requires clinicians and administrators to take joint responsibility for making sure this occurs.2

Australia has an excellent health care system, one of the best in the world. However, no health care system is perfect and on occasion, adverse events occur and errors are made. We have a positive obligation to prevent them from occurring. Clinical governance is the system tool which should act as a "safety-net" in order to prevent adverse events occurring and to effect change such that improvements can be made.

There have been two recent reports which have touched on the issue of clinical governance:

This article discusses each case briefly and draws out the clinical governance lessons for health and aged care providers, so that they may learn from these experiences to improve future patient outcomes.

  1. Review of Serious Failures in Reported Test Results or PSA

The Australian Commission on Safety and Quality in Health Care published its report titled "Review of Serious Failures in Reported Test Results for Prostate-specific Antigen (PSA) Testing of Patients by SA Pathology" in July 2016. The Report is discussed below.

1.1 Facts

  1. From March 2015, SA Pathology began reporting levels of Prostate-specific Aantigen (PSA) in patients at low levels following requests from urologists who found the results useful in monitoring their patients who had their prostates removed – as men without a prostate gland should have no detectable PSA. The presence of PSA, even at low levels, may indicate the need for further treatment.
  2. From 7 November 2015 the assay lots used by SA Pathology to detect PSA were inaccurate between the ranges of 0.03 – 0.08 micrograms per litre (ug/L) with a positive bias of 0.03 ug/L. Consequently, the PSA results for patients reported from this date, within this range, showed detectable PSA levels where PSA was undetectable, and higher levels of PSA where there were low detectable levels. From 17 March 2016 SA Pathology reported tests on two different methods simultaneously.
  3. The report states that SA Pathology failed to act on the inaccurate PSA results despite technical warnings generated by their laboratory systems. One potential warning was inadvertently switched off and another was noted without its potential to detect the error being realised.
  4. SA Pathology did not become aware of the inaccurate results it was producing until a complaint from a urologist at the end of January 2016. The complaint was wrongly classified with a low level of severity and, although SA Pathology did take the appropriate action to determine the cause of the inaccurate readings, that action was slow and not consistent with the urgency of the situation.
  5. Complaints continued to be made to SA Pathology about PSA results through February and March 2016. SA Pathology determined to discontinue the defective test from six months after dual reporting was introduced. Until then, SA Pathology continued to report the inaccurate results to clinicians. On 18 March 2016, SA Pathology wrote to all urologists explaining the problem with the test and the move to a new test, and placed a notice on the SA Pathology website. The public notice was framed as a routine notice without sufficient explanation to be considered as adequate notification to the public.
  6. The report found that SA Pathology's complaint handling, open disclosure, governance and accountability systems during this period was totally inadequate.
  7. Following media exposure of the issue in early April 2016, significant and appropriate action was taken by SA Pathology. A "lookback" process was commenced to identify the number of patients affected by the inaccurate tests.
  8. The review found the management structure of SA Pathology did not provide for sufficient clinical supervision of, and accountability for, laboratory process. The review was briefed regarding a separate management review of SA Pathology which considered SA Pathology's structure dysfunctional and different from contemporary management structures in place in pathology laboratories throughout Australia.
  9. The review's expert chemical pathologist analysed data from SA Pathology and determined that the test kits in question were inaccurate at levels of 0.03 – 0.08 ug/L. As these kits were distributed to a number of laboratories in Australia, the review has provided its expert advice to the manufacturer and the Therapeutic Goods Administration.

1.2. Summary of Major Findings

The review made the following findings:

  1. SA Pathology's internal quality assurance processes were inadequate. SA Pathology failed to act on technical warnings from the laboratory system that the tests were inaccurate in low level PSA test results from assay kits in use from 7 November 2015. No action was taken until a complaint from a urologist in late January 2016.
  2. The complaint was not given the appropriate level of attention and SA Pathology's investigations were slow. When SA Pathology did finally determine that the problem resulted from the test kits it was using, its action to notify affected users was totally inadequate and failed to appreciate the anxiety and distress of the inaccurate results on those patients who received the results.
  3. When the issue received public attention, appropriate action was, and has since been taken, to identify the patients affected and notify their treating clinicians.
  4. Management, governance and accountability at SA Pathology was seriously deficient. The review agrees with the findings and proposals of a separate management review recommended a restructure to bring SA Pathology in line with management practices in place at comparable Australian providers.

1.3. Clinical Governance Lessons

  1. The review found that SA Pathology failed to properly monitor and respond to the alerts from its automated testing.
  2. Whilst concern was mounting among urologists and their patients who were calling SA Pathology to express their concern, these calls were not formally treated as complaints as they should have been, and consequently there were no entries in Q-Pulse and the Safety Learning System.
  3. The classification of the first complaint with a severity assessment code of 4 was inconsistent with the serious nature of the issue and the potential number of patients affected. The low classification also had the result that more senior staff in both SA Pathology and SA Health were not notified and did not have the opportunity to consider how it should be managed.
  4. The clinical significance of the inaccurate low level PSA readings was not appreciated and action to investigate the cause was not pursued with any sense of urgency.
  5. The severity of the problem was underrated resulting in no senior level notification and investigation as required by policies. There was no attempt to identify affected patients and no attempt to develop a comprehensive plan to notify them despite the knowledge that the inaccurate tests result could lead to misdiagnosis and unnecessary treatment.
  6. During the review it became apparent that the structure of the organisation did not provide sufficient clinical input and management accountability at appropriate levels, and quality assurance procedures were not sufficient to identify emerging issues and problems and ensure appropriate management.
  7. The review included a recommendation to engage an appropriately qualified and experienced person to implement an organisation structure for SA Pathology that:
    1. aligns appropriately skilled staff placement with the operational needs of the service;
    2. provides adequate clinical expertise to monitor and inform the production of results;
    3. clearly defines the responsibilities and accountabilities of staff; and
    4. ensures the requirements of referring clinicians are re?ected in the work rules of the service.
  1. Bankstown-Lidcombe Hospital Medical Gas Findings Report

2.1 Facts

  1. The NSW Chief Health Officer's Final Report into the Bankstown-Lidcombe Hospital medical gas incident was released on 27 August 2016 and found a series of tragic errors led to the failed resuscitation of two babies.
  2. One of the babies died and the other has been left with serious health issues.
  3. Dr Kerry Chant's report was provided to the families of the two babies on Friday morning, 26 August.
  4. The two babies were born at Bankstown-Lidcombe Hospital earlier this year – one in June and the other in July. Both babies needed resuscitation after birth.

2.2 Major Findings

  1. Dr Chant's report found that mislabelling of existing gas pipes resulting in incorrect installation of additional medical gas pipes in one of the Bankstown-Lidcombe Hospital's operating theatres, which was not picked up during installation or by the testing and commissioning of the pipes, led to the two babies being resuscitated with nitrous oxide instead of oxygen. The process of testing for gas purity is the ultimate test to ensure that the right gas comes out of the right outlets.

2.3 Clinical Governance Lessons

  1. The report also found broader clinical and corporate governance issues at the Hospital, specifically around the project planning and risk management of the commissioning of clinical infrastructure.
  2. A recommendation was to review senior management's role in the broader governance (both clinical and corporate) of the commissioning of clinical infrastructure at the hospitals.

Commentary and Summary of Clinical Governance Lessons Learnt

There are some common clinical governance themes which run through these two cases, including as follows:

  1. In each case, there was an indicator that there was an issue, however, for one reason or another, the issue was not escalated appropriately to senior management. Health care providers must ensure that there is adequate ability for staff to notify their concerns to senior management, through a number of alterative avenues and staff should be trained on severity indicators.
  2. Involving a multi-disciplinary team is important because the team provides peer review and a check and balance.
  3. It is really important to check that what you are doing is in accordance with a manner that (at the time the service was provided) was widely accepted in Australia by peer professional opinion as competent professional practice. This was an issue in both cases.
  4. In one of the cases disharmony in culture appears to be a contributing factor.
  5. In one of the cases, for various reasons, there was a delay in dealing with the issue once it was raised to senior management. If there is a significant issue, then the matter needs to be escalated and dealt with urgently by senior management.
  6. Adverse event reporting, investigation, root cause analysis, look back, open disclosure and communication and media policies should be in place and followed.
  7. In both cases, management accountability is raised.
  8. In both cases, the use of technology, such as software, could have been used to identify the issue.


2 Definition derived from the Clinical Governance web page on the NSW Ministry of Health website (

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions